EDP Sciences logo
Rechercher
Menu
All issues Volume 25 / No 4 (2013) Ann Toxicol Anal, 25 4 (2013) 175-184 References
Open Access
Issue
Ann Toxicol Anal
Volume 25, Number 4, 2013
Page(s) 175 - 184
DOI https://doi.org/10.1051/ata/2013052
Published online 26 March 2014
  1. Documents consultés sur le site http://www.swgdrug.org/Monographs/UR144.pdf et http://www.forensicdrugreview.com/2 le 2 juillet 2013. [Google Scholar]
  2. Richard D, Senon J-L, Valleur M. Dictionnaire des drogues et des dépendances. Larousse 2009 : 447. [Google Scholar]
  3. EMCDDA. Online sales of new psychoactive substances/‘legal highs’ : summary of results from the 2011 multilingual snapshots. Publications Office of the European Union 2011. [Google Scholar]
  4. Document consulté sur le site http://www.emcdda.europa.eu/publications/drug-profiles/kratom le 3 juillet 2013. [Google Scholar]
  5. OICS. Rapport de l’Organe international de contrôle des stupéfiants pour 2012. Publication des Nations unies 2013. [Google Scholar]
  6. EMCDDA. New drugs in Europe, 2012. EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA. Publications Office of the European Union 2013. [Google Scholar]
  7. OFDT. Tendances n° 84 – janvier 2013. [Google Scholar]
  8. Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007; 53 : 439–452. [CrossRef] [PubMed] [Google Scholar]
  9. Nichols DE. Hallucinogens. Pharmacol Ther. 2004; 101 : 131–181. [CrossRef] [PubMed] [Google Scholar]
  10. Pertz HH, Heim R, Elz S. N-benzylated phenylethanamines are highly potent partial agonists at 5-HT2A receptors. Arch Pharm Pharm Med Chem. 2000; 333 : 30. [Google Scholar]
  11. http://www.swgdrug.org/monographs.htm [Google Scholar]
  12. Zuba D, Sekula K, Buczek A. 25C-NBOMe – New potent hallucinogenic substance identified on the drug market. Forensic Sci Int. 2013; 227(1-3) : 7–14. [CrossRef] [PubMed] [Google Scholar]
  13. Casale JF, Hays PA. Characterization of eleven 2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) derivatives and differentiation from their 3- and 4-methoxybenzyl analogues – Part I. Microgram J. 2012; 9(2) : 84–109. [Google Scholar]
  14. Silva ME. Theoretical study of the interaction of agonists with the 5-HT2A receptor. Thèse de doctorat de l’Université de Regensburg, 2008. [Google Scholar]
  15. Document consulté sur le site http://www.drugs-forum.com/forum/showthread.php?t=200378 le 2 juillet 2013. [Google Scholar]
  16. Document consulté sur le site http://www.bluelight.ru/vb/threads/626411-Rh-34 le 2 juillet 2013. [Google Scholar]
  17. Zuba D, Sekuła K. Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Testing Anal. 2013; 5(8) : 634–645. [CrossRef] [Google Scholar]
  18. Shulgin A, Shulgin A. PiHKAL : A chemical love story. Transform Press : 1991. [Google Scholar]
  19. Clark CC. The differentiation of lysergic acid diethylamide (LSD) from N-methyl-N-propyl and N-butyl amides of lysergic acid. J Forensic Sci. 1989; 34(3) : 532–546. [Google Scholar]
  20. WO application 2006069196. Pace JM, Tietje K, Dart MJ, Meyer MD. 3-cycloalkylcarbonyl indoles as cannabinoid receptor lignad. 29/06/2006. [Google Scholar]
  21. Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, El-Kouhen OF, Yao BB, Hsieh GC, Pai M, Zhu CZ, Chandran P, Meyer MD. Indol-3-ylcycloalkyl ketones : effects of N1 substituted indole side chain variations on CB2 cannabinoid receptor activity. J Med Chem. 2010; 53(1) : 295–315. [Google Scholar]
  22. OFDT. Bulletin d’information SINTES n° 01/12. Mai 2012. [Google Scholar]
  23. Kavanaugh P, Grigoryev A, Savcuck S, Mikhura I, Formanovsky A. UR-144 in products sold via the Internet : Identification of related compounds and characterization of pyrolysis products. Drug Testing Anal. 2013; 5(8) : 683–692. [CrossRef] [Google Scholar]